Actively Recruiting
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
Led by UMC Utrecht · Updated on 2024-12-27
34
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
Sponsors
U
UMC Utrecht
Lead Sponsor
M
Maastricht University, MERLN Institute for Technology-Inspired Regenerative Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine. Participants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample withdrawal * Urine sample collection * 12-hour urine collection Then, one to four weeks after starting with furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample prior to furosemide intake (Tmin) * Blood sample withdrawal 90 minutes after furosemide intake (Tmax: time at which the highest furosemide plasma level is expected) * Urine sample collection 60-120 minutes after furosemide intake * 12-hour urine collection The investigators expect furosemide to increase plasma levels of PBUTs by decreasing the renal excretion of the toxins.
CONDITIONS
Official Title
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of chronic kidney disease stage 3-5 with eGFR below 60 mL/min/1.73m2 for at least three months
- Indication to start furosemide treatment as part of routine care
- Willingness to participate and signed informed consent
You will not qualify if you...
- Current use of furosemide treatment
- Liver disease with hyperbilirubinemia
- Receiving any type of renal replacement therapy (peritoneal dialysis, haemodialysis)
- End-stage renal failure without residual urine production
- Starting medications simultaneously with furosemide that may affect PBUT excretion or binding
- Incapacity to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Utrecht (UMCU)
Utrecht, Utrecht, Netherlands, 3584 CX
Actively Recruiting
Research Team
D
Dian P Bolhuis, MD, MSc
CONTACT
K
Karin GF Gerritsen, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here